Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials

Archives of Gynecology and Obstetrics

Volumn 298, Issue 4, 2018, Pages 675-684

  Laganà, Antonio Simone ^a   Vitagliano, Amerigo ^b   Noventa, Marco ^b   Ambrosini, Guido ^b   D’Anna, Rosario ^c  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Controlled ovarian hyperstimulation; In vitro fertilization; Myo inositol; Recombinant follicle stimulating hormone

Indexed keywords

GONADORELIN; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; INOSITOL; RECOMBINANT FOLLITROPIN;

DIET SUPPLEMENTATION; GONADOTROPIN BLOOD LEVEL; HUMAN; IN VITRO FERTILIZATION; META ANALYSIS; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; DIETARY SUPPLEMENT; FEMALE; PATHOPHYSIOLOGY; PROCEDURES;

DIETARY SUPPLEMENTS; FEMALE; FERTILIZATION IN VITRO; GONADOTROPINS; HUMANS; INOSITOL; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85051658188     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-018-4861-y     Document Type: Review

References (31)

1. Bizzarri M, Fuso A, Dinicola S, Cucina A, Bevilacqua A (2016) Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Expert Opin Drug Metab Toxicol 12:1181–1196. 10.1080/17425255.2016.1206887
2. Hatch AJ, York JD (2010) SnapShot: inositol phosphates. Cell 143(1030–1030):e1. 10.1016/j.cell.2010.11.045
3. Di Paolo G, De Camilli P (2006) Phosphoinositides in cell regulation and membrane dynamics. Nature 443:651–657. 10.1038/nature05185
4. Sortino MA, Salomone S, Carruba MO, Drago F (2017) Polycystic ovary syndrome: insights into the therapeutic approach with inositols. Front Pharmacol 8:341. 10.3389/fphar.2017.00341
5. Chakraborty A, Kim S, Snyder SH (2011) Inositol pyrophosphates as mammalian cell signals. Sci Signal 4:re1. 10.1126/scisignal.2001958
6. Noventa M, Vitagliano A, Quaranta M, Borgato S, Abdulrahim B, Gizzo S (2016) Preventive and therapeutic role of dietary inositol supplementation in periconceptional period and during pregnancy: a summary of evidences and future applications. Reprod Sci 23:278–288. 10.1177/1933719115594018
7. Paul C, Laganà AS, Maniglio P, Triolo O, Brady DM (2016) Inositol’s and other nutraceuticals’ synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. Gynecol Endocrinol 32:431–438. 10.3109/09513590.2016
8. Vitagliano A, Noventa M, Gizzo S (2015) Is it time to consider patients suffering from endometriosis-related infertility as “novel candidates” for targeted peri-conceptional d-chiro inositol supplementation? Hypothesis, rationale and some considerations. J Assist Reprod Genet 32:407–408. 10.1007/s10815-014-0412-z
9. Pizzo A, Laganà AS, Barbaro L (2014) Comparison between effects of myo-inositol and d-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol 30:205–208. 10.3109/09513590.2013.860120
10. Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L (2009) Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 91:1750–1754. 10.1016/j.fertnstert.2008.01.088
11. Colazingari S, Treglia M, Najjar R, Bevilacqua A (2013) The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet 288:1405–1411. 10.1007/s00404-013-2855-3
12. Pacchiarotti A, Carlomagno G, Antonini G, Pacchiarotti A (2016) Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecol Endocrinol 32:69–73. 10.3109/09513590.2015.1101444
13. Mendoza N, Pérez L, Simoncini T, Genazzani A (2017) Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials. Reprod Biomed Online 35:529–535. 10.1016/j.rbmo.2017.07.005
14. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. 10.1371/journal.pmed.1000097
15. Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from http://handbook.cochrane.org
16. Rizzo P, Raffone E, Benedetto V (2010) Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol 14:555–561
17. Ciotta L, Stracquadanio M, Pagano I, Carbonaro A, Palumbo M, Gulino F (2011) Effects of Myo-Inositol supplementation on oocyte’s quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci 15:509–514
18. Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S (2011) Myo-inositol rather than d-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci 15:452–457
19. Carlomagno G, Oliva MM, Roseff SJ, Unfer V (2012) Myo-inositol: ovarian stimulation and IVF outcomes. Fertil Steril 98:S74–S75. 10.1016/j.fertnstert.2012.07.270
20. Lisi F, Carfagna P, Oliva MM, Rago R, Lisi R, Poverini R, Manna C, Vaquero E, Caserta D, Raparelli V, Marci R, Moscarini M (2012) Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol 10:52. 10.1186/1477-7827-10-52
21. Schillaci R, Mangione D, Lo Monte G, Vassiliadis A (2012) Inositol supplementation and IVF outcome: preliminary data. Ital J Gynaecol Obstet 21:38–44
22. Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, Cela V (2013) Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol 29:375–379. 10.3109/09513590.2012.743020
23. Caprio F, D’Eufemia MD, Trotta C, Campitiello MR, Ianniello R, Mele D, Colacurci N (2015) Myo-inositol therapy for poor-responders during IVF: a prospective controlled observational trial. J Ovarian Res 8:37. 10.1186/s13048-015-0167-x
24. Lesoine B, Regidor PA (2016) Prospective randomized study on the influence of myoinositol in PCOS women undergoing IVF in the improvement of oocyte quality, fertilization rate, and embryo quality. Int J Endocrinol 2016:4378507. 10.1155/2016/4378507
25. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25
26. Unfer V, Carlomagno G, Dante G, Facchinetti F (2012) Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 28:509–515. 10.3109/09513590.2011.650660
27. Unfer V, Nestler JE, Kamenov ZA, Prapas N, Facchinetti F (2016) Effects of Inositol(s) in women with PCOS: a systematic review of randomized controlled trials. Int J Endocrinol 2016:1849162. 10.1155/2016/1849162
28. Zheng X, Lin D, Zhang Y, Lin Y, Song J, Li S, Sun Y (2017) Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Medicine (Baltimore) 96:e8842. 10.1097/MD.0000000000008842
29. Busnelli A, Papaleo E, Del Prato D, La Vecchia I, Iachini E, Paffoni A, Candiani M, Somigliana E (2015) A retrospective evaluation of prognosis and cost-effectiveness of IVF in poor responders according to the Bologna criteria. Hum Reprod 30:315–322. 10.1093/humrep/deu319
30. Zivi E, Simon A, Laufer N (2010) Ovarian hyperstimulation syndrome: definition, incidence, and classification. Semin Reprod Med 28:441–447. 10.1055/s-0030-1265669
31. Csokmay JM, Yauger BJ, Henne MB, Armstrong AY, Queenan JT, Segars JH (2010) Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: “Tap early and often” versus hospitalization. Fertil Steril 93:167–173. 10.1016/j.fertnstert.2008.09.054